Rationale of extracorporeal removal of endotoxin in sepsis: Theory, timing and technique

Contributions to Nephrology

Volumn 167, Issue , 2010, Pages 25-34

  Ronco, Claudio ^a,b   Piccinni, Pasquale ^a,b   Kellum, John ^c  

^a SAN BORTOLO HOSPITAL   (Italy)

^b International Renal Research Institute Vicenza (IRRIV)   (Italy)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ENDOTOXIN;

ADULT RESPIRATORY DISTRESS SYNDROME; ANIMAL; ANIMAL MODEL; BACTEREMIA; BIOLOGICAL MODEL; BLOOD; CARDIOVASCULAR SYSTEM; ENDOTOXEMIA; GRAM NEGATIVE INFECTION; HEART LEFT VENTRICLE FUNCTION; HEMOPERFUSION; HUMAN; ISOLATION AND PURIFICATION; KIDNEY; LUNG; METHODOLOGY; MORTALITY; PATHOPHYSIOLOGY; REVIEW; SEPSIS; SEPTIC SHOCK;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTEREMIA; CARDIOVASCULAR SYSTEM; ENDOTOXEMIA; ENDOTOXINS; GRAM-NEGATIVE BACTERIAL INFECTIONS; HEMOPERFUSION; HUMANS; KIDNEY; LUNG; MODELS, ANIMAL; MODELS, BIOLOGICAL; RESPIRATORY DISTRESS SYNDROME, ADULT; SEPSIS; SHOCK, SEPTIC; VENTRICULAR DYSFUNCTION, LEFT;

EID: 77954583228     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000315916     Document Type: Article

References (33)

1. Lowry SF: Human endotoxemia: a model for mechanistic insight and therapeutic targeting. Shock 2005;24(Suppl 1):94-100.
2. Suffredini AF, Shelhamer JH, Neumann RD, Brenner M, Baltaro RJ, Parillo JE: Pulmonary and oxygen transport effects of intravenously administered endotoxin in normal humans. Am Rev Respir Dis 1992;145:1398-1403.
3. Smith PD, Suffredini AF, Allen JB, Wahl LM, Parillo JE, Wahl SM: Endotoxin administration to humans primes alveolar macrophages for increased production of inflammatory mediators. J Clin Immunol 1994;14:141-148.
4. Richardson RP, Rhyne CD, Fong Y, Hesse DG, Tracey KJ, Marano MA, Lowry SF, Antonacci AC, Calvano SE: Peripheral blood leukocyte kinetics following in vivo lipopolysaccharide (LPS) administration to normal human subjects: influence of elicited hormones and cytokines. Ann Surg 1989;210:239-245.
5. Suffredini AF, Fromm RE, Parker MM, Brenner M, Kovacs JA, Wesley RA, Parrillo JE: the cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med 1989;321:280-287.
6. Aras O, Shet A, Bach RR, Hysjulien JL, Slungaard A, Hebbel RP, Escol G, Jilma B, Key NS: Induction of microparticle- and cell-associated intravascular tissue factor in human endotoxemia. Blood 2004;103: 4545-4553.
7. Kumar A, Thota V, Dee L, Olson J, Uretz E, Parillo JE: Tumor necrosis factor-alpha and interleukin 1-beta are responsible for in vitro myocardial cell depression induced by human septic shock serum. J Exp Med 1996;183:949-958.
8. Giroir BP, Johnson JH, Brown T, Allen GL, Beutler B: The tissue distribution of tumor necrosis factor biosynthesis during endotoxemia. J Clin Invest 1992;90:693-698.
9. Meldrum DR: Tumor necrosis factor in the heart. Am J Physiol 1998;274:R577-R595.
10. Smith PD, Suffredini AF, Allen JB, Wahl LM, Parillo JE, Wahl SM: Endotoxin administration to humans primes alveolar macrophages for increased production of inflammatory mediators. J Clin Immunol 1994;14:141-148.
11. Jo SK, Cha DR, Cho WY, Kim HK, Chang KH, Yun SY, Won NH: Inflammatory cytokines and lipopolysaccharide induce Fas-mediated apoptosis in renal tubular cells. Nephron 2002;91:406-415.
12. Guo R, Wang Y, Minto AW, Quigg RJ, Cunningham PN: Acute renal failure in endotoxemia is dependent on caspase activation. J Am Soc Nephrol 2004;15:3093-3102.
13. Wesche-Soldato DE, Swan RZ, Chung CS, Ayala A: The apoptotic pathway as a therapeutic target in sepsis. Curr Drug Targets 2007;8:493-500.
14. Bordoni V, Bolgan I, Brendolan A, Crepaldi C, Gastaldon F, D'Intini V, Pilotto L, Inguaggiato P, Bonello M, Galloni E, Everard P, Bellomo R, Ronco C: Caspase-3 and -8 activation and cytokine removal with a novel cellulose triacetate superpermeable membrane in an in vitro sepsis model. Int J Artif Organs 2003;26:897-905.
15. Camussi G, Mariano F, Biancone L, De Martino A, Bussolati B, Montrucchio G, Tobias PS: Lipopolysaccharide binding protein and CD14 modulate the synthesis of platelet-activating factor by human monocytes and mesangial and endothelial cells stimulated with lipopolysaccharide. J Immunol 1995;155:316-324.
16. Cantaluppi V, Assenzio B, Pasero D, Romanazzi GM, Pacitti A, Lanfranco G, Puntorieri V, Martin EL, Mascia L, Monti G, Casella G, Segoloni GP, Camussi G, Ranieri VM: Polymyxin-B hemoperfusion inactivates circulating proapoptotic factors. Intensive Care Med 2008;34:1638-1645.
17. Stumacher RJ, Kovnat MJ, McCabe WR: Limitations of the usefulness of the limulus assay for endotoxin. N Engl J Med 1973;283: 1261-1264.
18. Jorgensen JH: Clinical applications of the limulus amebocyte lysate test; in Proctor RA (ed): Clinical Aspects of Endotoxin Shock: Handbook of Endotoxin. Amsterdam, Elsevier, 1986, vol 4, pp 127-160.
19. Herring WB, Herion JC, Walker RI, Palmer JG: Distribution and clearance of circulating endotoxin. J Clin Invest 1963;43:79-87.
20. Opal SM, Scannon OJ, Vincent JL, White M, Carroll SF, Palardy JE, Parejo NA, Pribble JP, Lemke JH: Relationship between plasma levels of LPS and LPS-binding protein in patients with severe sepsis and septic shock. J Infect Dis 1999;180:1584-1589.
21. Hurley JC: Endotoxemia: methods of detection and clinical correlates. Clin Microbiol Rev 1995;8:268-292.
22. Danner RL, Elin RJ, Hosseini JM, Wesley RA, Reilly JM, Parillo JE: Endotoxemia in human septic shock. Chest 1991;99:169-175.
23. Stephens RC, O'Malley CM, Frumento RJ, et al: Low-dose endotoxin elicits variability in the inflammatory response in healthy volunteers. J Endotoxin Res 2005;11:207-212.
24. Coyle SM, Calvano SE, Lowry SF: Gender influences in vivo human responses to endotoxin. Shock 2006;26:538-543.
25. Marshall JC, Foster D, Vincent JL, et al: Diagnostic and prognostic implications of endotoxemia in critical illness: results of the MEDIC study. J Infect Dis 2004;190:527-534.
26. Klein DJ, Derzko A, Foster D, Seely AJE, Brunet F, Romaschin AD, Marshall JC: Daily variation in endotoxin levels is associated with increased organ failure in critically ill patients. Shock 2007;28:524-529.
27. Brock-Utne JG, Gaffin SL, Wells MT, et al: Endotoxaemia in exhausted runners after a long-distance race. S Afr Med J 1988;73: 533-536.
28. Hasday JD, Bascom R, Costa JJ, et al: Bacterial endotoxin is an active component of cigarette smoke. Chest 1999;115:829-835.
29. Opal SM, Gluck T: Endotoxin as a drug target. Crit Care Med 2003;31(Suppl 1):57-64.
30. Cohen J: The detection and interpretation of endotoxemia. Intensive Care Med 2000; 26(Suppl 1):S51-S56.
31. Ziegler EJ, Fisher CJ, Sprung CL, et al: Treatment of Gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med 1991;324:429-436.
32. Cruz DN, Perazella MA, Bellomo R, de Cal M, Polanco N, Corradi V, Lentini P, Nalesso F, Ueno T, Ranieri VM, Ronco C: Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review. Critical Care 2007;11:R47.
33. Cruz DN, Antonelli M, Fumagalli R, et al: Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 2009;301: 2445-2452.